2019
Genomic characteristics of deleterious BRCA1 and BRCA2 alterations and associations with baseline clinical factors in patients with metastatic castration-resistant prostate cancer (mCRPC) enrolled in TRITON2.
Abida W, Bryce A, Vogelzang N, Amato R, Percent I, Shapiro J, McDermott R, Hussain A, Patnaik A, Petrylak D, Ryan C, Stanton T, Zhang J, Loehr A, Simmons A, Despain D, Golsorkhi A, Watkins S, Scher H, Chowdhury S. Genomic characteristics of deleterious BRCA1 and BRCA2 alterations and associations with baseline clinical factors in patients with metastatic castration-resistant prostate cancer (mCRPC) enrolled in TRITON2. Journal Of Clinical Oncology 2019, 37: 5031-5031. DOI: 10.1200/jco.2019.37.15_suppl.5031.Peer-Reviewed Original ResearchMetastatic castration-resistant prostate cancerBaseline clinical characteristicsDNA damage repair genesClinical characteristicsBRCA1 patientsProstate-specific antigen levelCastration-resistant prostate cancerBaseline clinical factorsMeasurable tumor burdenDeleterious alterationsGenomic alterationsCo-occurring alterationsRepair genesNext-generation sequencing assayBRCA alterationsMCRPC patientsBaseline PSAPSA levelsClinical factorsTumor burdenDeleterious germlineAntigen levelsBRCA mutationsBRCA2 alterationsDeleterious BRCA1
2018
TRITON2: An international, multicenter, open-label, phase II study of the PARP inhibitor rucaparib in patients with metastatic castration-resistant prostate cancer (mCRPC) associated with homologous recombination deficiency (HRD).
Abida W, Bryce A, Balar A, Chatta G, Dawson N, Guancial E, Hussain A, Jha G, Lipsitz D, Patnaik A, Petrylak D, Ryan C, Stanton T, Vogelzang N, Zhang J, Simmons A, Go J, Golsorkhi T, Chowdhury S, Scher H. TRITON2: An international, multicenter, open-label, phase II study of the PARP inhibitor rucaparib in patients with metastatic castration-resistant prostate cancer (mCRPC) associated with homologous recombination deficiency (HRD). Journal Of Clinical Oncology 2018, 36: tps388-tps388. DOI: 10.1200/jco.2018.36.6_suppl.tps388.Peer-Reviewed Original ResearchMetastatic castration-resistant prostate cancerHomologous recombination deficiencyNodal diseaseDeleterious germlineProstate cancerProstate-specific antigen (PSA) responseRadiographic progression-free survivalCastration-resistant prostate cancerDNA repair genesClinical benefit rateObjective response ratePhase 2 studyPhase II studyProgression-free survivalTaxane-based chemotherapyHomologous recombination (HR) DNA repair genesPlatinum-based chemotherapyPretreatment blood samplesAdvanced prostate cancerDuration of responseSoft tissue diseaseRepair genesPrimary endpointSecondary endpointsII studyTRITON3: An international, randomized, open-label, phase III study of the PARP inhibitor rucaparib vs. physician’s choice of therapy for patients with metastatic castration-resistant prostate cancer (mCRPC) associated with homologous recombination deficiency (HRD).
Ryan C, Abida W, Bryce A, Balar A, Dumbadze I, Given R, Morris D, Petrylak D, Redfern C, Scher H, Watkins S, Simmons A, Passler L, Golsorkhi T, Chowdhury S. TRITON3: An international, randomized, open-label, phase III study of the PARP inhibitor rucaparib vs. physician’s choice of therapy for patients with metastatic castration-resistant prostate cancer (mCRPC) associated with homologous recombination deficiency (HRD). Journal Of Clinical Oncology 2018, 36: tps389-tps389. DOI: 10.1200/jco.2018.36.6_suppl.tps389.Peer-Reviewed Original ResearchMetastatic castration-resistant prostate cancerHomologous recombination deficiencyIndependent radiology reviewHomologous recombination (HR) DNA repair genesPhysician's choiceRadiology reviewDeleterious germlineProstate cancerRadiographic progression-free survivalCastration-resistant prostate cancerDNA repair genesObjective response rateProgression-free survivalPretreatment blood samplesAdvanced prostate cancerDuration of responsePatient-reported outcomesRepair genesMCRPC settingSecondary endpointsPrimary endpointRadiographic progressionOverall survivalComparator treatmentSomatic BRCA1